Myelofibrosis
235
48
75
96
Key Insights
Highlights
Success Rate
76% trial completion
Published Results
63 trials with published results (27%)
Research Maturity
96 completed trials (41% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
12.8%
30 terminated out of 235 trials
76.2%
-10.4% vs benchmark
8%
18 trials in Phase 3/4
66%
63 of 96 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 96 completed trials
Clinical Trials (235)
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis
Haplo-HSCT for Myelofibrosis
A Telehealth Advance Care Planning Intervention
Peri-graft Cytokine Profile: Influence of Hematologic Disease and Donor Type
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis
QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants
Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis